AU567236B2 - Pharmaceutical formulation of tissue plasminogen activator - Google Patents

Pharmaceutical formulation of tissue plasminogen activator

Info

Publication number
AU567236B2
AU567236B2 AU57964/86A AU5796486A AU567236B2 AU 567236 B2 AU567236 B2 AU 567236B2 AU 57964/86 A AU57964/86 A AU 57964/86A AU 5796486 A AU5796486 A AU 5796486A AU 567236 B2 AU567236 B2 AU 567236B2
Authority
AU
Australia
Prior art keywords
pharmaceutical formulation
plasminogen activator
tissue plasminogen
tissue
activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU57964/86A
Other languages
English (en)
Other versions
AU5796486A (en
Inventor
Henry Berger
Michael Denis Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521705A external-priority patent/GB8521705D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU5796486A publication Critical patent/AU5796486A/en
Application granted granted Critical
Publication of AU567236B2 publication Critical patent/AU567236B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU57964/86A 1985-05-28 1986-05-27 Pharmaceutical formulation of tissue plasminogen activator Ceased AU567236B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB8513358 1985-05-28
GB858521705A GB8521705D0 (en) 1985-08-31 1985-08-31 Formulation
GB8521705 1985-08-31

Publications (2)

Publication Number Publication Date
AU5796486A AU5796486A (en) 1986-12-04
AU567236B2 true AU567236B2 (en) 1987-11-12

Family

ID=26289290

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57964/86A Ceased AU567236B2 (en) 1985-05-28 1986-05-27 Pharmaceutical formulation of tissue plasminogen activator

Country Status (22)

Country Link
US (2) US4929444A (OSRAM)
JP (1) JPH0759517B2 (OSRAM)
AU (1) AU567236B2 (OSRAM)
BE (1) BE904830A (OSRAM)
CA (1) CA1300008C (OSRAM)
CH (1) CH665356A5 (OSRAM)
DE (1) DE3617752A1 (OSRAM)
DK (1) DK163173C (OSRAM)
ES (2) ES8800601A1 (OSRAM)
FI (1) FI85335C (OSRAM)
FR (1) FR2583984B1 (OSRAM)
GB (1) GB2176702B (OSRAM)
GR (1) GR861366B (OSRAM)
HU (1) HU195733B (OSRAM)
IL (1) IL78938A (OSRAM)
IT (1) IT1191926B (OSRAM)
LU (1) LU86444A1 (OSRAM)
NL (1) NL8601355A (OSRAM)
NO (1) NO171345C (OSRAM)
NZ (1) NZ216307A (OSRAM)
PT (1) PT82646B (OSRAM)
SE (1) SE462016B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO171344C (no) * 1985-05-28 1993-03-03 Wellcome Found Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
JPH0680015B2 (ja) * 1986-05-12 1994-10-12 ザ ウエルカム ファウンデーション リミテッド 医薬組成物
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
WO1992011866A1 (en) * 1991-01-14 1992-07-23 Duke University LAMININ SEQUENCE AS tPA ACTIVATOR
DE69333127T2 (de) * 1992-06-03 2004-05-06 Genentech, Inc., South San Francisco Varianten des Gewebeplasminogenaktivators mit verbesserter therapeutischer Wirkung
JP3840262B2 (ja) * 1995-10-23 2006-11-01 ザ チルドレンズ メディカル センター コーポレイション 治療用の抗血管新生組成物および方法
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
KR100477280B1 (ko) * 1995-12-13 2005-07-18 아보트 러보러터리즈 맥관형성에의한질환치료제
DE69719265T2 (de) * 1996-09-06 2003-12-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
EP1636337A4 (en) * 2003-06-20 2007-07-04 Illumina Inc METHODS AND COMPOSITIONS USEFUL FOR THE AMPLIFICATION AND GENOTYPING OF THE GENOME
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
US8822535B2 (en) * 2005-04-20 2014-09-02 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5330286A (en) * 1985-02-09 1986-08-14 Beecham Group Plc Modified tissue-type plasminogen activator
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (OSRAM) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
EP0124613B1 (en) * 1982-10-29 1992-12-30 MITSUI TOATSU CHEMICALS, Inc. Novel plasminogen activator derived from human kidneys, process for its preparation, and thrombolytic drug containing the same
NZ206699A (en) * 1982-12-30 1989-08-29 Bio Response Inc Process for the production of serum independent cell lines
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
GB8513358D0 (en) * 1985-05-28 1985-07-03 Wellcome Found Formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
AU5330286A (en) * 1985-02-09 1986-08-14 Beecham Group Plc Modified tissue-type plasminogen activator

Also Published As

Publication number Publication date
FR2583984B1 (fr) 1989-06-02
PT82646B (pt) 1989-01-30
GB2176702B (en) 1989-07-05
SE8602405D0 (sv) 1986-05-27
GB2176702A (en) 1987-01-07
FR2583984A1 (fr) 1987-01-02
AU5796486A (en) 1986-12-04
IT1191926B (it) 1988-03-31
SE462016B (sv) 1990-04-30
LU86444A1 (fr) 1986-12-05
IL78938A0 (en) 1986-09-30
IL78938A (en) 1993-02-21
DE3617752A1 (de) 1986-12-04
DK163173C (da) 1992-06-22
FI862227L (fi) 1986-11-29
IT8648065A0 (it) 1986-05-27
ES8800601A1 (es) 1987-11-16
NO171345C (no) 1993-03-03
NO171345B (no) 1992-11-23
US4929444A (en) 1990-05-29
HU195733B (en) 1988-07-28
CA1300008C (en) 1992-05-05
US4968617A (en) 1990-11-06
GR861366B (en) 1986-09-29
NO862096L (no) 1986-12-01
BE904830A (fr) 1986-11-27
PT82646A (en) 1986-06-01
FI862227A0 (fi) 1986-05-27
DK246786A (da) 1986-11-29
GB8612780D0 (en) 1986-07-02
ES555353A0 (es) 1987-11-16
NL8601355A (nl) 1986-12-16
CH665356A5 (de) 1988-05-13
DK163173B (da) 1992-02-03
ES557374A0 (es) 1988-06-01
JPH06183995A (ja) 1994-07-05
DK246786D0 (da) 1986-05-27
NZ216307A (en) 1989-10-27
FI85335C (fi) 1992-04-10
HUT41638A (en) 1987-05-28
JPH0759517B2 (ja) 1995-06-28
DE3617752C2 (OSRAM) 1988-06-30
SE8602405L (sv) 1986-11-29
FI85335B (fi) 1991-12-31
ES8802439A1 (es) 1988-06-01

Similar Documents

Publication Publication Date Title
AU5796486A (en) Pharmaceutical formulation of tissue plasminogen activator
AU588365B2 (en) Pharmaceutical compositions and medical uses of dioxopiperidine derivatives
NO171344C (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator
AU571372B2 (en) Gel based delivery of active substances
AU609390B2 (en) Cyclodextrinclathrates of carbacycline derivatives and their use as medicinal drugs
AU4434589A (en) Pharmaceutical compositions containing salts of cholesterol hemisuccinate
AU6110286A (en) Poly-kringle plasminogen activator
EP0196920A3 (en) Degraded species of tissue-type plasminogen activator, pharmaceutical composition and method of preparation
AU6806487A (en) Tissue plasminogen activator
AU581010B2 (en) Novel pharmaceutical use of (NVA)``-cyclosporine
AU2690684A (en) Methods and pharmaceutical compositions for the treatment of hyperplastic diseases of the skin
ZA867839B (en) Biologically active derivatives of human ypsilon-interferon
AU6180486A (en) Novel tissue plasminogen activator derivatives
AU4486189A (en) Oral liquid pharmaceutical compositions of sulindac
AU5953090A (en) Novel use of 1-phenyl-2-aminoethanol derivatives as healing agents
AU1892788A (en) Improvements relating to measurement of tissue plasminogen activator activity
AU570582B2 (en) Pharmaceutical composition of flupirtine and 4-acetamidophenol
ZA863956B (en) Pharmaceutical formulations containing tissue plasminogen activator
AU6656886A (en) Pharmaceutical composition of suprofen
AU7090787A (en) Tissue plasminogen activator
IL79521A0 (en) Pharmaceutical dosage unit of tissue plasminogen activator
IL78450A0 (en) Agent containing tissue plasminogen activator(t-pa)
AU5367786A (en) New method of analgesic treatment and new pharmaceutical compositions
AU8305787A (en) Therapeutic use of enkephalinase
AU7696087A (en) Recombinant human tissue plasminogen activator composition